NIH to Review Intramural Program NCI's Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.

May 17, 2024

Vol.50 No.20

By Jacquelyn Cobb

Conversation with The Cancer Letter

NCI’s Lisa McShane: We need to understand the implications of HRD assay discordance

Homologous recombination deficiency tests are available from multiple vendors, and every day they are used to determine whether patients stand to benefit from PARP inhibitors.

RWE study pinpoints gaps in mental health care utilization among parents of children with cancer

Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents of children with cancer use mental health services.

May 17, 2024

Vol.50 No.20

By McKenzie Prillaman

Capitol Hill

Sen. Durbin weighs in on the controversy about dosage of Amgen drug sotorasib

Sen. Richard J. Durbin (D-IL) has asked Amgen to provide copies of the company’s communications with FDA related to the dosage of Lumakras (sotorasib), a KRAS inhibitor marketed under an accelerated approval for non-small cell lung cancer.

Regulators must step in to safeguard patient data in the AI era

The healthcare sector’s necessary transition towards electronic health records (EHRs) has transformed patient care and operational efficiency.

May 17, 2024

Vol.50 No.20

By Mika Newton

In Brief

Daniel Geynisman named editor-in-chief of JNCCN

Daniel M. Geynisman was named the editor-in-chief of JNCCN—Journal of the National Comprehensive Cancer Network.

May 17, 2024

Vol.50 No.20

NIH to Review Intramural Program

NCI's Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

YOU MAY BE INTERESTED IN

HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices

NCI’s Lisa McShane: We need to understand the implications of HRD assay discordance

RWE study pinpoints gaps in mental health care utilization among parents of children with cancer

Sen. Durbin weighs in on the controversy about dosage of Amgen drug sotorasib

Regulators must step in to safeguard patient data in the AI era

Daniel Geynisman named editor-in-chief of JNCCN

Renew today!

Subscriber content

Login